Management of hyperlipidemia in patients with vascular disease (Q35157129)

6 August 2017

title

Management of hyperlipidemia in patients with vascular disease (English)

1 reference

6 August 2017

1 reference

Maria C Cote

1

1 reference

6 August 2017

Robert Ligeti

series ordinal

2

1 reference

6 August 2017

Bruce S Cutler

series ordinal

3

1 reference

6 August 2017

Peter R Nelson

series ordinal

4

1 reference

6 August 2017

publication date

1 June 2003

1 reference

Journal of Vascular Nursing

6 August 2017

published in

1 reference

6 August 2017

volume

21

1 reference

6 August 2017

issue

2

1 reference

6 August 2017

page(s)

63-7; quiz 68-9

1 reference

Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Kuopio Atherosclerosis Prevention Study (KAPS). A population-based primary preventive trial of the effect of LDL lowering on atherosclerotic progression in carotid and femoral arteries

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Pravastatin, Lipids, and Atherosclerosis in the Carotid Arteries (PLAC-II)

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): Reduction in atherosclerosis progression and clinical events

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Intermittent claudication. Incidence in the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Rationale and design of the Cardiac Hospitalization Atherosclerosis Management Program at the University of California Los Angeles.

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Optimizing treatment of dyslipidemia in patients with coronary artery disease in the managed-care environment (the Rocky Mountain Kaiser Permanente experience).

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

Lipid management in a private cardiology practice (the Midwest Heart experience).

1 reference

https://api.crossref.org/works/10.1016%2FS1062-0303%2803%2900035-9

7 January 2021

10.1016/S1062-0303(03)00035-9

Identifiers

DOI

1 reference

6 August 2017

1 reference